ArticleFrontiers in endocrinology2025
Predictive value of the triglyceride-glucose index for adverse clinical outcomes in chronic kidney disease.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clustering-derived clinical subtypes and outcomes of chronic kidney disease in patients with diabetes: a multicenter cohort study.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The triglyceride-glucose (TyG) index has been proposed as a reliable marker of insulin resistance. However, clinical significance of the TyG index in patients with chronic kidney disease (CKD) remains unclear. Methods: A total of 47,592 individuals with CKD who underwent nationwide health examinations between 2012 and 2015 were enrolled. Patients were classified into four quartiles based on their TyG index levels. The association between the TyG index and cardiovascular (CV) events, progression to end-stage kidney disease (ESKD), and all-cause mortality was evaluated. Results: A higher TyG index was associated with an increased risk of CV events. Compared with patients in the lowest TyG index quartile, hazard ratios (HRs) and 95% confidence intervals (CIs) for CV events were 1.08 (1.00-1.17), 1.13 (1.04-1.22), and 1.39 (1.28-1.51) for the second, third, and fourth quartiles, respectively. The risk of progression to ESKD also increased with higher TyG quartiles, with adjusted HRs (95% CIs) of 1.22 (1.08-1.38), 1.35 (1.18-1.54), and 1.86 (1.65-2.10) across increasing TyG index quartiles. The risk of all-cause mortality was similarly elevated in patients in the highest TyG index quartile. Furthermore, the risks of ESKD progression and all-cause mortality across different levels of kidney function was more pronounced with increasing TyG index levels (all P for interaction< 0.001). Conclusion: TyG index is a valuable predictor of CV event, progression to ESKD, and all-cause mortality in patients with CKD, and it significantly interacted with kidney function in relation to the risks of ESKD and mortality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.